SRPT analyst estimates
Sarepta Therapeutics (SRPT) analyst ratings, the average price target and its range, and every firm's latest call.
SRPT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Sarepta price target lowered to $17 from $19 at RBC Capital | $17.00 |
| Jul 27, 2026 | Morgan Stanley | Morgan Stanley says Sarepta's CEO transition brings clarity ahead of catalysts | $25.00 |
| Jul 9, 2026 | Piper Sandler | Sarepta price target lowered to $20 from $23 at Piper Sandler | $20.00 |
| Jul 8, 2026 | Wolfe Research | Sarepta upgraded to Outperform from Peer Perform at Wolfe Research | $27.00 |
| May 15, 2026 | Evercore ISI | Sarepta price target lowered to $19 from $20 at Evercore ISI | $19.00 |
| Mar 26, 2026 | Wedbush | Sarepta price target raised to $35 from $29 at Wedbush | $35.00 |
| Mar 26, 2026 | Deutsche Bank | Deutsche ups Sarepta target, says 35% stock rally overdone | $14.00 |
| Mar 12, 2026 | Mizuho Securities | Sarepta Therapeutics (SRPT) PT Raised to $31 at Mizuho | $31.00 |
| Mar 3, 2026 | Jefferies | Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story" | $30.00 |
| Mar 3, 2026 | Loop Capital Markets | Sarepta Therapeutics (SRPT) PT Raised to $25 at Freedom Capital Markets | $25.00 |
| Jan 27, 2026 | Robert W. Baird | Sarepta price target raised to $22 from $15 at Baird | $22.00 |
| Dec 9, 2025 | Wedbush | Wedbush bullish on Sarepta, initiates with an Outperform | $32.00 |
| Nov 25, 2025 | Bernstein | Sarepta price target raised to $20 from $18 at Bernstein | $20.00 |
| Nov 5, 2025 | Mizuho Securities | Mizuho Upgrades Sarepta Therapeutics (SRPT) to Outperform | $26.00 |
| Nov 5, 2025 | Barclays | Sarepta price target lowered to $20 from $22 at Barclays | $20.00 |
- 14 firms rate SRPT: 6 buy, 5 hold, 3 sell.
- The average price target is $21.60 from 5 analysts, from $17.00 to $27.00.
Updated 2026-11-03 11:31 UTC